Therapeutic bacterial metabolites as natural GLP-1 agonists
Development of a safe, oral therapeutic using bacterial metabolites that act as natural GLP-1 agonists to reduce weight. Proven efficacy in mice with potential for human application. Seeking partners for research sponsorship and licensing.
Overview
The proposed solution leverages therapeutic bacterial metabolites formulated as short chain fatty acids (SCFAs) that function as natural GLP-1 agonists. These compounds have demonstrated significant weight reduction effects in mice, even with a continuous high-fat diet, suggesting a potent and safe therapeutic avenue for obesity management in humans. The solution aims to translate these findings into a clinical context, offering a novel, oral treatment option for obesity.
Technical specifications
Key features include:
- Short chain fatty acid formulation: Demonstrated 15-20% weight reduction in mice over a 3-month period.
- Mechanism of action: Functions as a GLP-1 agonist; further studies aim to elucidate additional mechanisms.
- Safety profile: No observed toxicity or adverse effects in mice and preliminary human studies, with no impact on food or water intake.
The therapeutic is embedded in solid food for easy administration. Ongoing research focuses on understanding the precise mechanisms of action through multi-omics studies targeting organs such as the heart, liver, and pancreas, with implications for diabetes and general health.
Technology readiness level
The technology is currently at TRL 3, indicating it is in the early stages of research and development. Preclinical validation is underway, with anticipated completion in 18-24 months. The organization seeks sponsorship for further research and potential licensing opportunities to transition towards clinical trials and eventual commercialization.
About SFA Therapeutics
SFA Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Jenkintown, Pennsylvania. The company utilizes a proprietary deuteration platform to develop oral, small-molecule biosynthetic compounds derived from short-chain fatty acids. Its core technology is designed to reset the immune system by modulating inflammatory factors through the gut-immune axis, specifically targeting the differentiation of T-regulatory (Treg) cells. By creating patentable new chemical entities, SFA aims to provide therapeutic solutions for chronic inflammatory, autoimmune, and oncological conditions. The company’s pipeline includes nine drug candidates, with its lead asset, SFA-002, currently being evaluated for the treatment of psoriasis.
This technology addresses significant unmet needs in markets such as psoriasis, metabolic dysfunction-associated steatohepatitis (MASH), and various cancers, offering a potential alternative to treatments that rely on chronic immune suppression. SFA Therapeutics has demonstrated early clinical proof-of-concept through positive Phase 1b trial data for SFA-002, which showed significant efficacy and a clean safety profile. Supported by an extensive intellectual property portfolio comprising granted and pending patents, the company is actively advancing its pipeline toward Phase 2 clinical trials and seeking strategic partnerships to accelerate the development and commercialization of its immunomodulatory therapeutics.
delivered to your inbox.